The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2012Regulated GDNF Gene Therapy: A Novel Regulatory System Based on Protein Degradation
Promising Outcomes of Original Grant:
We have developed lentiviral vectors that can express functional GDNF both in the cell culture dish and in the brain of pre-clinical models. These vectors can be... -
Rapid Response Innovation Awards, 2012Ceruloplasmin Deamidation in Parkinson’s Disease Cerebrospinal Fluid: Gain of Pro-adhesive Function
Objective/Rationale:
We demonstrated that Ceruloplasmin (Cp), an enzyme present in cerebrospinal fluid (CSF), is oxidized in the CSF of PD patients. Among oxidative modifications, the asparagine... -
Neurotrophic Factors Challenge, 2012Pre-clinical Validation of a Nurr1 Agonist for Neuroprotection in Parkinson’s Disease
Objective/Rationale:
Studies in PD patients have shown that increased cellular levels of α-syn are associated with reduced levels of Nurr1, and that mutations in the Nurr1 gene that have...
-
Resource: Utilizing Samples from the Arizona Parkinson’s Dis, 2012Neurotrophic and Autophagic Markers in Parkinson’s Disease: Implications for Disease-modifying Strategies
Objective/Rationale:
GDNF is a potent survival factor for dopamine (DA) neurons, effective in standard neurotoxin models of PD, but recent studies show that GDNF is unable to rescue DA...
-
Rapid Response Innovation Awards, 2012Evaluation of the Effects of Human Cell Derived GM1 Ganglioside in the MPTP Lesioned Pre-clinical Model of Parkinson's Disease
Objective/Rationale:
The objective of this study is to evaluate the effects of human cell derived GM1 (hGM1) ganglioside in the treatment of a pre-clinical model of Parkinsons disease (PD)... -
Dyskinesia LEAPS, 2012Development of L-745,870, a Selective D4 Receptor Antagonist, for the Treatment of Levodopa-induced Dyskinesia
Objective/Rationale:
In the 1980s and 90s a novel drug, L-745,870 was developed for the treatment of psychosis in schizophrenia. L-745,870 has excellent characteristics for a drug, and a selective...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.